Navigation Links
GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
Date:10/8/2007

, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2006.

Anacor Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected closing of the collaboration agreement, GlaxoSmithKline's financing commitment to Anacor, the discovery, development and commercialization of novel medicines pursuant to the collaboration, future payments of milestone and royalty amounts to Anacor and the potential of Anacor's boron-based chemistry to inhibit targets that are difficult to address with traditional carbon-based molecules or have developed resistance to currently available treatments. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Some factors that may affect these forward-looking statements include, but are not limited to, the ability of the parties to collaborate successfully to develop drug candidates, the results of future drug discovery, development and commercialization efforts, including proof of safety and efficacy in clinical trials, the ability to obtain regulatory approvals for drug candidates identified through the collaboration, and the introduction of competing therapies by other companies. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking state
'/>"/>

SOURCE Anacor Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Biomedical Alliance about more than stem cells
5. Doyle seeks $2.5M for biomedical alliance
6. Alliance looks to create the right chemistry in SE Wisconsin
7. Biomedical alliance marks first full year
8. New alliance to provide Wi-Fi network for City of Madison
9. Budget axe could cut SE Wisconsin tech alliance funding
10. Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
11. Milwaukee research alliance sees need for incubator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the investment ... announced the hiring of William Tanner as ... Mr. Tanner will start work at Guggenheim in ... office. "Bill brings a wealth ... to our experienced and highly acclaimed healthcare team," said ...
(Date:4/17/2015)... MIAMI (PRWEB) April 17, 2015 ... attend the GTCbio Stem Cell Summit 2015 April 27 ... present the latest developments in all areas of stem ... business of stem cells and regenerative medicine. , ... clinical trials, as well as translational research in stem ...
(Date:4/17/2015)... 17, 2015 BellBrook Labs announced ... support for the powerful Orthogonal Pooled Screening (OPS) ... Center at the Lankenau Institute for Medical Research ... to measurably improve successful drug discovery outcomes using ... rare, drug-like libraries available nowhere else, coupled to ...
(Date:4/16/2015)... and OSAKA, Japan , April ... Application (CiRA) of Kyoto University and Takeda Pharmaceutical ... work together to develop clinical applications of induced ... failure, diabetes mellitus, neurological disorders and cancer immunotherapy. ... (T-CiRA) is designed to expedite multiple research projects ...
Breaking Biology Technology:Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
... MYL ),today announced that Mylan Pharmaceuticals Inc. has ... (FDA) for its Abbreviated New,Drug Application (ANDA) for Ropinirole ... (base), 2 mg (base), 3 mg (base), 4 mg ... the generic version of,GlaxoSmithKline,s Requip(R) Tablets, which had total ...
... to Acquire Commercialized Thrombolytic and Related Assets for $17 ... ... Therapeutics, Inc.,(Nasdaq: IMRX ) today announced that it has signed a ... from ImaRx for $17 million in cash. Urokinase is an FDA-approved,thrombolytic, or ...
... ER May Impact Employment Status, WASHINGTON, ... (paliperidone ER) spent significantly,fewer days in the ... office visits, and fewer psychotherapy sessions,compared with ... a new,analysis of data presented at the ...
Cached Biology Technology:ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 2ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 3ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 4Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 2Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 3Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 4Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 5Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 6
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... make poisons similar to those found in rattlesnake venom ... (Monday 8 September 2008) at the Society for General ... College, Dublin. The toxins are manufactured by communities ... are up to a thousand times more resistant to ...
... new method to fabricate borosilicate glass nanoparticles. ... are more stable when subjected to temperature ... used nanoparticles made of polymers or silica ... of potential nanoparticle applications in biomedical, optical ...
... Science Foundation has awarded Iowa State University and ... to establish the NSF Engineering Research Center for ... award is part of the National Science Foundation,s ... third-generation Engineering Research Centers are designed to create ...
Cached Biology News:Rattlesnake-type poisons used by superbug bacteria to beat our defenses 2Rattlesnake-type poisons used by superbug bacteria to beat our defenses 3Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 2Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 3Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 4